Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
Status:
Completed
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
This study is an extension to the HP-CD-CL-2002 clinical study. It evaluates the long-term
safety and tolerability of CDNF in patients with Parkinson's disease when dosed directly into
the brain using an implanted investigational drug delivery system (DDS). Long-term safety of
the DDS is also being evaluated. All patients will receive monthly infusions of either mid-
or high-dose of CDNF for a period of 6 months.